A research agenda to promote affordable and quality assured medicines

Promoting generic medicines to increase access to essential medicines is relevant to achieve the Millennium Development Goal (MDGs) and post 2015 goals.

There are several barriers to encouraging wider use of generic medicines in health systems, e.g. the widely-held perception that low price equals low quality and misalignment of provider and consumer incentives. Overcoming the complex barriers and other challenges can be re-formulated as a ‘generic medicine evidence-based policy agenda’: (1) What policy and strategies can increase consumer trust in the quality of all medicines granted market authority including generic products? (2) Are there differences in prices between branded and unbranded generics? (3) What are synergies between policies that can enhance promoting of generic medicines effectively?

Evaluating the policies promoting generic medicines will be critical to create evidence that countries can use to implement policies in their local settings.

Promoting generic medicines to increase access to essential medicines is relevant to achieve the Millennium Development Goal (MDGs) and post 2015 goals.

There are several barriers to encouraging wider use of generic medicines in health systems, e.g. the widely-held perception that low price equals low quality and misalignment of provider and consumer incentives. Overcoming the complex barriers and other challenges can be re-formulated as a ‘generic medicine evidence-based policy agenda’: (1) What policy and strategies can increase consumer trust in the quality of all medicines granted market authority including generic products? (2) Are there differences in prices between branded and unbranded generics? (3) What are synergies between policies that can enhance promoting of generic medicines effectively?

Evaluating the policies promoting generic medicines will be critical to create evidence that countries can use to implement policies in their local settings.